As I posted previously, I believe QCOR's stock is range-bound for a while. On the one hand, earnings and revenue will be increasing at a fantastic rate.But all the market sees is risk. And I don't disagree to an extent. I believe insurance carriers will continue to try to get out of reimbursing for Acthar. I think on the whole, they will be largely unsuccessful since Questcor's sales staff seems to have a lock on the reimbursement process. But the fear is there, and it'll only get worse to 2017.The earnings are real, and that should provide a floor to the stock price. Therefore, I continue to write puts and calls.Carl
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Ma